SCHEMBL852047

SCHEMBL852047

[c]1[c]c2c(cc1)Sc1ccccc1N2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 10/20 0.55
MAPT P10636 7/20 0.55
GAA P10253 6/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
SNCA P37840 3/20 0.55
ALOX15 P16050 3/20 0.55
BCHE P06276 2/20 0.55
ACHE P22303 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
CYP1A2 P05177 2/20 0.55
POLB P06746 1/20 0.55
CYP3A4 P08684 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
ALOX12 P18054 1/20 0.55
MAOA P21397 1/20 0.55
CNR1 P21554 1/20 0.55
PTGS1 P23219 1/20 0.55
SLC6A2 P23975 1/20 0.55
HTR2C P28335 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4651 0.78 NOX1 (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL1664650 0.77 NOX1 (0.53) NOX1MAPTGAAMEN1KMT2A
SCHEMBL28535050 0.76 NOX1 (0.57) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL29352248 0.73 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL6315328 0.73 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL29349533 0.73 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL2504207 0.73 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL9114 0.73 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
SCHEMBL28860617 0.72 NOX1 (0.52) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL23683396 0.71 NOX1 (0.94) NOX1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159244-B1 ANTHRACENE POLYMER COMPOUND AND LIGHT-EMITTING DEVICE USING THE SAME SUMITOMO CHEMICAL CO (JP) 2016-11-23 EP claimed
US-8513877-B2 Anthracene polymer compound and light emitting device using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-08-20 US claimed
US-20110284829-A1 POLYMER COMPOUND AND LIGHT EMITTING DEVICE USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-11-24 US claimed
US-20100156284-A1 ANTHRACENE POLYMER COMPOUND AND LIGHT EMITTING DEVICE USING THE SAME SUMITOMO CHEMICAL COMPANY ,LIMITED (JP) 2010-06-24 US claimed
US-20100109517-A1 PYRENE POLYMER COMPOUND AND LIGHT EMITTING DEVICE USING THE SAME SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-05-06 US claimed
EP-2159244-A1 ANTHRACENE POLYMER COMPOUND AND LIGHT-EMITTING DEVICE USING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-03-03 EP claimed
EP-2147944-A1 PYRENE POLYMER AND LUMINESCENT ELEMENT MADE WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-27 EP claimed
US-6946207-B2 Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device CANON KABUSHIKI KAISHA (JP) 2005-09-20 US claimed
US-20020135292-A1 Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device CANON KABUSHIKI KAISHA (JP) 2002-09-26 US claimed
US-20240197888-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-06-20 US disclosed
WO-2024120442-A1 PAK4 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CONVERGEN (SUZHOU) PHARMACEUTICAL CO., LTD. (CN) 2024-06-13 WO disclosed
US-20240190885-A1 KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX INC (US) 2024-06-13 US disclosed
WO-2024120467-A1 PHOSPHORAMIDATE MONOSACCHARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS SURIO THERAPEUTICS CO. LTD (CN) 2024-06-13 WO disclosed
US-20240190883-A1 KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2024-06-13 US disclosed
US-20020183374-A1 Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-12-05 US disclosed
US-20020135292-A1 Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device CANON KABUSHIKI KAISHA (JP) 2002-09-26 US disclosed
WO-2002072557-A1 BIS(TRIFLUOROMETHYL)HYDANTOINS AS INTERMEDIATES FOR PHARMACEUTICALLY ACTIVE INGREDIENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-09-19 WO disclosed
EP-1174430-A1 Process for the preparation of heterocycles by using C1-building blocks Universität Konstanz (DE) 2002-01-23 EP disclosed
US-6051722-A PRECURSOR FOR POLYIMIDE COPOLYMER; USABLE IN OPTICAL LONG-DISTANCE COMMUNICATION, SIGNAL PROCESSING, PHOTOELECTRIC HYBRID CIRCUITS AND OPTICAL COMPUTERS HITACHI CHEMICAL COMPANY, LTD. (JP) 2000-04-18 US disclosed
US-5834575-A POLYIMIDE OR POLYACRYLATE WITH PENDANT GROUP CONTAINING THIOPHENE RING, BENZENE RING AND VICINAL NITRILE GROUPS, SWITCHES FOR OPTICAL SIGNALS, COMMUNICATION TECHNOLOGY HITACHI CHEMICAL COMPANY, LTD. (JP) 1998-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190885-A1 KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS KRAS, NRAS, APC NOX1 4401/4885MAPT 1586/4885GAA 311/4885
US-20020183374-A1 Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients HRH1, ALDH7A1, HRH4 NOX1 4100/4885MAPT 2859/4885GAA 1526/4885
US-20240197888-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS SOS1, SOS2, SOST NOX1 1770/4885MAPT 989/4885GAA 561/4885
US-20100109517-A1 PYRENE POLYMER COMPOUND AND LIGHT EMITTING DEVICE USING THE SAME TERB1, AHR, CYP1A1 NOX1 1111/4885MAPT 881/4885GAA 3812/4885
US-20240190883-A1 KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS KRAS, NRAS, APC NOX1 4449/4885MAPT 1609/4885GAA 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.